- Home
- ELAB vs CARM Comparison
ELAB vs CARM Comparison
Compare ELAB & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- CARM
- Stock Information
- Founded
- ELAB 2020
- CARM 2016
- Country
- ELAB United States
- CARM United States
- Employees
- ELAB N/A
- CARM N/A
- Industry
- ELAB
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- ELAB
- CARM Health Care
- Exchange
- ELAB Nasdaq
- CARM Nasdaq
- Market Cap
- ELAB 6.6M
- CARM 7.7M
- IPO Year
- ELAB 2023
- CARM N/A
- Fundamental
- Price
- ELAB $2.17
- CARM $0.19
- Analyst Decision
- ELAB
- CARM Hold
- Analyst Count
- ELAB 0
- CARM 5
- Target Price
- ELAB N/A
- CARM $0.90
- AVG Volume (30 Days)
- ELAB 77.7K
- CARM 911.4K
- Earning Date
- ELAB 05-14-2025
- CARM 05-13-2025
- Dividend Yield
- ELAB N/A
- CARM N/A
- EPS Growth
- ELAB N/A
- CARM N/A
- EPS
- ELAB N/A
- CARM N/A
- Revenue
- ELAB N/A
- CARM $19,964,000.00
- Revenue This Year
- ELAB N/A
- CARM N/A
- Revenue Next Year
- ELAB N/A
- CARM N/A
- P/E Ratio
- ELAB N/A
- CARM N/A
- Revenue Growth
- ELAB N/A
- CARM 32.45
- 52 Week Low
- ELAB $1.95
- CARM $0.14
- 52 Week High
- ELAB $939.96
- CARM $1.90
- Technical
- Relative Strength Index (RSI)
- ELAB 37.11
- CARM 48.12
- Support Level
- ELAB $2.06
- CARM $0.17
- Resistance Level
- ELAB $2.23
- CARM $0.21
- Average True Range (ATR)
- ELAB 0.18
- CARM 0.02
- MACD
- ELAB 0.05
- CARM 0.00
- Stochastic Oscillator
- ELAB 29.92
- CARM 66.44
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.